Reviving HER3 ADC: Insights from JCO Literature Review
After the announcement of the failed Phase III study HERTHENA-Lung02 of HER3 ADC at this year’s ASCO, what does it matter if you win the world? Discussing the HER3 ADC HERTHENA-lung02 study [2025 ASCO], I thought that the drug Patritumab Deruxtecan might have come to a halt. Unexpectedly, while reading literature recently, I found that … Read more